📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. (2022)

First Author: Gershenson DM

Attributed to: Precision medicine and the mutational landscape of high grade serous ovarian cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02175-9

PubMed Identifier: 35123694

Publication URI: http://europepmc.org/abstract/MED/35123694

Type: Journal Article/Review

Volume: 399

Parent Publication: Lancet (London, England)

Issue: 10324

ISSN: 0140-6736